Numerous papers have been published on the HEPATIQ® indices. Two of the most important clinical trials, HALT-C and A2ALL, were prospective trials sponsored by the NIH and performed at prestigious academic institutions. The HALT-C showed that the PHM® and fSV® indices predict clinical outcomes and out-perform any combination of blood tests and biopsies. The A2ALL showed that the PHM® and fLV® indices track liver function and volume in serial measurements during liver regeneration.
Some recent publications are reporting on the limitations of fibrosis scoring. Listed below are the key points from some of these publications. Please click on any of these key points for details of the publication. For more on the research, please contact sales@hepatiq.com.
